Latest Posts

• New Accelerator Aims For Social Change With AR, VR, Gaming Startups

  Games for Change, a non-profit that promotes the use of games and immersive technology for social good, is taking applications from startup teams for a new accelerator program it’s launching in New York City.

  New York-based Games for Change already... Read more »

  Bernadette Tansey3/20/19

• U.S. Energy Dept. Awards $500M Supercomputer Contract to Intel, Cray

  Computer chipmaker Intel and its subcontractor, Seattle-based Cray, say they expect a supercomputer they plan to eventually deliver will be a flop—an exaflop, that is.

  The U.S. Department of Energy’s Argonne National Laboratory has hired Intel (NASDAQ: INTC) and Cray... Read more »

  Jeff Buchanan3/19/19

• Why Comma.ai, Maker of Self-Driving Tech, is Moving to San Diego

  Tech salaries may not be as high outside of Silicon Valley, but neither is the cost of operating a business—or the cost of living.

  San Diego’s startup community has rejoiced in recent months as massive companies that employ thousands of engineers—including... Read more »

  Sarah de Crescenzo3/19/19

• Dermira Shares Soar After Eczema Drug Hits Goal of Mid-Stage Study

  An experimental drug developed by Dermira to treat atopic dermatitis has hit the main goal of its mid-stage study, helping to build a case that the injectable treatment could measure up against a drug from Regeneron Pharmaceuticals and Sanofi.

  Atopic dermatitis... Read more »

  Frank Vinluan3/18/19

• Qualcomm Gets $31M in Patent Infringement Trial Win Over Apple

  Wireless giant Qualcomm notched a win Friday in its ongoing multijurisdictional war with smartphone maker Apple as a federal jury in San Diego unanimously backed its patent infringement case.

  Qualcomm (NASDAQ: QCOM) said Friday that the jury found that some... Read more »

  Sarah de Crescenzo3/15/19

• M:Bility Conference: Panel Talks Factors Fueling Future of AV Industry

  At AutoWorld’s M:Bility conference in Dearborn, MI, this week, a wide variety of topics pertaining to the mobility industry and the development of driverless technology were covered in keynote and panel discussions, including mapping and sensors, artificial intelligence, automotive data, mobility-as-a-service,... Read more »

  Sarah Schmid Stevenson3/15/19

• Bio Roundup: Golumbeski’s Legacy, CRISPR Moratorium, Rebate Week & More

  While all eyes in the biopharmaceutical world are currently trained on Bristol-Myers Squibb’s proposal to buy Celgene for $74 billion, it wasn’t that long ago that another company’s gaze was fixed on the Summit, NJ, drug maker.

  In the early... Read more »

  Frank Vinluan3/15/19

• Keen, a San Antonio SaaS Startup Owned by Scaleworks, Hires New CEO

  San Antonio—Ben Kuhn has been promoted to become the CEO of Keen, a San Antonio startup that helps software developers with custom application programming interfaces for data collection and analytics.

  Kuhn was hired as the general manager of Keen in... Read more »

  David Holley3/14/19

• Harley-Davidson Goes Electric: Behind the Scenes of LiveWire’s R&D

  For more than a century, the throaty “potato, potato, potato” rumble of a Harley-Davidson motorcycle has been synonymous with the open road, freedom—rebellion, even—and, some might say, American masculinity.

  For non-gearheads, that iconic sound, introduced in 1909, is the result... Read more »

  Brian E. Clark3/14/19

• F5’s $670M Deal for Nginx Expands Firms’ Control of Web Servers, Apps

  Internet users are celebrating the World Wide Web’s 30th birthday this week by reminiscing about early Web technologies like America Online and dial-up modems. But users’ Web experiences—from the 1990s to today’s mobile and social media-dotted digital landscape—are only possible with... Read more »

  Jeff Buchanan3/13/19

• FDA Clears Aerie’s Combo Glaucoma Drug, But Will it Sell?

  The FDA late Tuesday approved a new type of glaucoma drug from Aerie Pharmaceuticals that, in clinical testing, beat the generic eye drops known as prostaglandin analogues (PGAs) that are typically prescribed to slow the progression of the disease.

  Now Aerie... Read more »

  Ben Fidler3/13/19

• The Investments Cisco, Samsung, Toyota, and Chevron Are Making in AI

  Austin—If you’re a startup talking up your artificial intelligence chops in your venture capital pitch, you’re not alone.

  For Cisco Investments, the venture arm of tech giant Cisco, artificial intelligence is no longer one of the key trends to watch... Read more »

  David Holley3/13/19

• Drug-Price Watchdog ICER Dives into Trump-Fueled Pharma Rebate Debate

  [Updated 3/13/19, 12:20pm. See below.] With public and political winds blowing in the same direction, significant reform of the complicated U.S. drug-pricing system seems ever more likely. One part of the system that the Trump administration wants to overhaul... Read more »

  Alex Lash3/13/19

Load More News ›

• The Life, Troubles, and Celgene Legacy of Deal Guru George Golumbeski

  George Golumbeski is one of the most prolific dealmakers in the biopharmaceutical world. But the deal that changed his life is a pact he made with himself when he was ten years old.

  Playing with friends in front of his house... Read more »

  Ben Fidler3/11/19

• Bio Roundup: Gottlieb Exits, Bristol Defends, Biogen Buys & More

  In early 2017, Scott Gottlieb was considered the most moderate of the potential candidates to head the Food and Drug Administration, which is the most powerful regulator of medical products in the world.

  It wasn’t a high bar to clear. Libertarians... Read more »

  Alex Lash3/8/19

• Bright Cellars Uncorks $8.5M Round for Wine Subscription Service

  A few years ago, the frothiest market in tech was arguably startups selling subscriptions to boxes of curated goods, such as clothing, beauty products, and food, which would arrive on customers’ doorsteps each month.

  The buzz around this area of... Read more »

  Jeff Engel3/7/19

• Steering Lyft’s IPO: What Investors Will Weigh During the Roadshow

  Much has been said about Lyft’s early lead over Uber in the “horserace” to become the first ride-hailing app company to go public. But now that San Francisco-based Lyft has filed its 276-page IPO prospectus with the U.S. Securities and Exchange... Read more »

  Bernadette Tansey and Sarah Schmid Stevenson3/7/19

• Apple Updates Plans, Now Expects to Create 1,200 Jobs in San Diego

  About three months ago, Apple announced it planned to add 1,000 jobs in the San Diego region over the next three years. On Wednesday, the Cupertino, CA-based tech giant said it would increase that total by 200 jobs as part of... Read more »

  Sarah de Crescenzo3/6/19

• Intel Reveals Ideas on Promoting AI in U.S. as Chinese Growth Looms

  Even as the executive order President Trump issued last month on artificial intelligence furthered the conversation about a developing national strategy for the sector, it was met with certain criticism. A common complaint was that the plan won’t implement itself.

  “The... Read more »

  David Holley3/6/19

• Joining AI Drug Discovery Race, Erasca Adds $22M For Cancer Work

  Erasca, a biotech startup run by the former CEO of Ignyta, debuted in December with $42 million and an audacious plan to “erase cancer,” but provided little explanation as to how.

  Erasca is still keeping many of those details under wraps.... Read more »

  Sarah de Crescenzo3/6/19

• Blue Squad Aims to Bring Election Tech Up and Down the Ballot

  Austin—All politics is local, the adage goes, and those campaigns are sorely stuck in analog mode.

  That’s why Shion Deysarkar co-founded Blue Squad two years ago as a “digital coalition” to support progressive candidates by providing them with greater access... Read more »

  Angela Shah3/6/19

• Two Years and Done: FDA Commissioner Gottlieb To Resign

  Two months after insisting on Twitter that he wasn’t going anywhere, Food and Drug Administration Commissioner Scott Gottlieb announced his resignation today. He leaves a record of health and medical regulation that was more active than critics who spoke out... Read more »

  Alex Lash3/5/19

Load More News ›

• Tasso Gets $6M For Device That Lets Users Self-Collect Blood Samples

  Tasso, a Seattle-based startup that is developing an at-home blood sample collection device, announced Tuesday it has raised $6.1 million from investors. The new money will support its effort to launch sales of the device, Tasso OnDemand, in the coming... Read more »

  Jeff Buchanan3/5/19

• Precision Bio Preps IPO to Test “Off-the-Shelf” Cancer Cell Therapy

  Precision BioSciences has filed for an initial public offering to continue its development of gene-edited cell therapies, including a cancer treatment that is set to start tests in humans in the coming months. The company is also forging ahead in gene... Read more »

  Frank Vinluan3/4/19

• Retailers Turn to Analytics, 3D Tech to Promote Fit, Reduce Returns

  One size fits most (at best), and a women’s sizing system created during the Depression doesn’t gibe in an e-commerce business that prizes personalization.

  That’s why startups are turning to new technologies like 3D scanning and machine learning software to produce... Read more »

  Angela Shah3/4/19

• Cybersecurity on Tap: Agenda for Cyber Madness in Boston April 8

  When it comes to cybersecurity, no one has all the answers. The best anyone can do is try to fend off cyber attacks with the latest technology and strategies, learn from their successes and failures, and maybe even share their experiences... Read more »

  Jeff Engel3/4/19

• After AGTC Deal Flops, Biogen Bets $800M on Gene Therapy Rival Nightstar

  Biogen’s biggest recent foray into gene therapy, an ill-fated pact with AGTC, didn’t pay dividends. So the company this morning agreed to buy a rival, Nightstar Therapeutics, and its portfolio of gene therapies for rare eye diseases, for $800 million.

  Biogen... Read more »

  Ben Fidler3/4/19

• Privacy Watch: FTC, Facebook, EU, the Cloud Act, & More CA bills

  Privacy issues continued to boil to the surface in February. In part, it’s a reflection of the long tail of consequences that began in early 2018 when the broader public learned that Facebook had shared data from millions of user profiles... Read more »

  Bernadette Tansey3/4/19

• SPECIAL REPORT: 2019 Biopharma Outlook – Facing an Uncertain Future

  After years of boom times, the U.S. biopharmaceutical industry is dealing with unprecedented threats on several fronts: public backlash against high drug prices, slowing sales, and the possibility of more government regulation.

  In this Xconomy Special Report, our veteran biotech journalists... Read more »

  Corie Lok3/1/19

• Bio Roundup: Pharma in DC, Bristol-Cel in Trouble, Roche Gets A Spark

  Could a shareholder revolt doom the planned marriage of Bristol-Myers Squibb and Celgene? Analysts have hinted at the possibility since the two companies shook hands in January, but the threat became real this week.

  Bristol (NYSE: BMY) and Celgene... Read more »

  Ben Fidler3/1/19

• Ex-Google CEO: New MIT College Could Help Shrink A.I. Talent Gap

  Eric Schmidt believes we’re entering an era where artificial intelligence will underpin most facets of human life. But we don’t yet have enough people with the right skills to build that future.

  Schmidt, the former CEO of Google and former executive... Read more »

  Jeff Engel2/28/19

Read More Posts ›